Changes in AXL and/or MITF melanoma subpopulations in patients receiving immunotherapy
2024

Changes in Melanoma Subpopulations During Immunotherapy

Sample size: 16 publication 10 minutes Evidence: moderate

Author Information

Author(s): Willemsen M., Bulgarelli J., Chauhan S.K., Lereim R.R., Angeli D., Grisendi G., Krebbers G., Davidson I., Kyte J.A., Guidoboni M., Luiten R.M., Bakker W.J.

Primary Institution: Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Cancer Center Amsterdam, Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, The Netherlands

Hypothesis

How do AXL+ and MITF+ melanoma subpopulations change in response to immunotherapy?

Conclusion

MITF+ melanoma cells are effectively targeted by immunotherapy, while AXL+ melanoma cells show resistance.

Supporting Evidence

  • MITF+ melanoma cells significantly decreased upon immunotherapy.
  • AXL+ melanoma cell numbers remained stable during treatment.
  • Changes in AXL+ or MITF+ tumor cells did not correlate with improved survival.

Takeaway

This study looked at different types of melanoma cells and found that some respond well to treatment while others do not.

Methodology

The study used NanoString gene expression analysis, single-cell RNA sequencing, and multiplex immunofluorescence to analyze tumor samples.

Potential Biases

Potential biases may arise from the limited number of patients and the variability in treatment responses.

Limitations

The study had a small sample size, which may limit the generalizability of the findings.

Participant Demographics

Patients included both males and females with varying ages and melanoma mutation statuses.

Statistical Information

P-Value

0.0494

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1016/j.iotech.2024.101009

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication